paroxetine has been researched along with amphetamine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Bertekap, R; Bronson, J; Davis, C; He, H; Lelas, S; Macor, JE; Newton, A; Taber, M; Wallace, T; Westphal, R; Wu, YJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Smith, DF | 1 |
| Bekkedal, M; Borkowski, C; Burgdorf, J; Panksepp, J; Turner, C | 1 |
| DeFelice, LJ; Ramsey, IS | 1 |
| Balcioglu, A; Tarazi, FI; Zhang, K | 1 |
| Chevrette, J; Harrison, AA; Hoyer, D; Markou, A | 1 |
| de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P | 1 |
| Bespalov, AY; Gross, G; Mezler, M; Schoemaker, H; Sukhotina, IA; van Gaalen, MM; Wicke, K | 1 |
| Friedman, A; Lax, E; Lubin, N; Merenlender, A; Rosenstein, M; Yadid, G | 1 |
| Cook, A; Forster, GL; Mears, M; Renner, KJ; Scholl, JL; Tu, W; Watt, MJ | 1 |
2 review(s) available for paroxetine and amphetamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Fluoxetine; GABA Agonists; Humans; Indans; Neuroprotective Agents; Paroxetine; Physostigmine; Piperidines; Piracetam; Pyridines; Selective Serotonin Reuptake Inhibitors; Serotonin; Stroke; Zolpidem | 2007 |
12 other study(ies) available for paroxetine and amphetamine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Topics: Antidepressive Agents; Astrocytes; Cell Line; HEK293 Cells; Humans; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2013 |
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
Topics: Alanine; Amphetamine; Aniline Compounds; Animals; Antidepressive Agents; Blood Platelets; Brain; Fluoxetine; Humans; Male; Methadone; Mianserin; Mirtazapine; Morpholines; Naphthalenes; Nefopam; Nomifensine; Paroxetine; Piperidines; Rabbits; Serotonin; Stereoisomerism; Tranylcypromine; Viloxazine; Zimeldine | 1986 |
Paradoxical effects of serotonin and opioids in pemoline-induced self-injurious behavior.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Drug Synergism; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Paroxetine; Pemoline; Rats; Rats, Sprague-Dawley; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Social Behavior; Time Factors | 1999 |
Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.
Topics: Amphetamine; Animals; Blotting, Western; Carrier Proteins; Cocaine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Recombinant Proteins; RNA, Complementary; Serotonin; Serotonin Plasma Membrane Transport Proteins; Xenopus laevis | 2002 |
Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Topics: Afferent Pathways; Amphetamine; Animals; Apomorphine; Binding, Competitive; Carrier Proteins; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Extracellular Matrix; Membrane Glycoproteins; Membrane Transport Proteins; Microdialysis; Neostriatum; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2003 |
Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.
Topics: Affective Symptoms; Aminopyridines; Amphetamine; Animals; Brain; Drug Synergism; Hypothalamus, Posterior; Male; Motivation; Norepinephrine; Paroxetine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reward; Selective Serotonin Reuptake Inhibitors; Self Stimulation; Serotonin 5-HT1 Receptor Antagonists; Substance Withdrawal Syndrome | 2005 |
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Darkness; Depression; Diazepam; Fever; Fluoxetine; Light; Male; Mice; Paroxetine; Receptors, Metabotropic Glutamate; Reinforcement Schedule; Stress, Psychological; Xanthenes | 2008 |
Early prediction of the effectiveness of antidepressants: inputs from an animal model.
Topics: Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Desipramine; Dopamine Agents; Female; Humans; Male; Models, Animal; Motor Activity; Paroxetine; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2009 |
Serotonin in the ventral hippocampus modulates anxiety-like behavior during amphetamine withdrawal.
Topics: 5,7-Dihydroxytryptamine; Amphetamine; Amphetamine-Related Disorders; Animals; Anxiety; Central Nervous System Stimulants; Disease Models, Animal; Hippocampus; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Substance Withdrawal Syndrome | 2014 |